Reduced_VBN
mitogenic_JJ
stimulation_NN
of_IN
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
as_IN
a_DT
prognostic_JJ
parameter_NN
for_IN
the_DT
course_NN
of_IN
breast_NN
cancer_NN
:_:
a_DT
prospective_JJ
longitudinal_JJ
study_NN
._.

Immunosuppression_NN
has_VBZ
been_VBN
often_RB
associated_VBN
with_IN
the_DT
course_NN
of_IN
malignant_JJ
diseases_NNS
._.

In_IN
the_DT
present_JJ
study_NN
,_,
the_DT
proliferation_NN
of_IN
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
-LRB-_-LRB-
PBMCs_NNS
-RRB-_-RRB-
in_IN
response_NN
to_TO
mitogenic_JJ
stimulation_NN
with_IN
phytohaemagglutinin_NN
-LRB-_-LRB-
PHA_NN
-RRB-_-RRB-
was_VBD
assessed_VBN
prospectively_RB
in_IN
90_CD
patients_NNS
with_IN
stage_NN
I-III_CD
breast_NN
cancer_NN
._.

Whereas_IN
PHA-induced_JJ
proliferation_NN
of_IN
PBMCs_NNS
derived_VBN
from_IN
patients_NNS
with_IN
breast_NN
cancer_NN
preoperatively_RB
was_VBD
significantly_RB
decreased_VBN
when_WRB
compared_VBN
with_IN
data_NNS
obtained_VBN
in_IN
healthy_JJ
control_NN
individuals_NNS
-LRB-_-LRB-
P_NN
&lt;_JJR
0.001_CD
-RRB-_-RRB-
,_,
the_DT
degree_NN
of_IN
the_DT
defect_NN
in_IN
PHA-induced_JJ
proliferation_NN
of_IN
PBMCs_NNS
depended_VBD
upon_IN
the_DT
tumor_NN
burden_NN
as_IN
manifested_VBN
by_IN
tumor_NN
size_NN
and_CC
axillary_JJ
lymph_NN
node_NN
involvement_NN
-LRB-_-LRB-
P_NN
&lt;_JJR
0.003_CD
in_IN
each_DT
case_NN
-RRB-_-RRB-
._.

PHA-induced_JJ
proliferation_NN
of_IN
PBMCs_NNS
dropped_VBD
significantly_RB
in_IN
patients_NNS
who_WP
received_VBD
adjuvant_JJ
chemotherapy_NN
consisting_VBG
of_IN
cyclophosphamide_NN
,_,
methotrexate_NN
and_CC
fluorouracil_NN
-LRB-_-LRB-
CMF_NN
-RRB-_-RRB-
after_IN
an_DT
observation_NN
period_NN
of_IN
6_CD
months_NNS
-LRB-_-LRB-
P_NN
&lt;_JJR
0.01_CD
-RRB-_-RRB-
,_,
but_CC
not_RB
in_IN
patients_NNS
under_IN
adjuvant_JJ
treatment_NN
with_IN
tamoxifen_NN
only_RB
._.

After_IN
an_DT
additional_JJ
6_CD
months_NNS
-LRB-_-LRB-
i.e._FW
12_CD
months_NNS
after_IN
surgery_NN
-RRB-_-RRB-
,_,
PHA-induced_JJ
proliferation_NN
of_IN
PBMCs_NNS
was_VBD
similar_JJ
in_IN
patients_NNS
after_IN
adjuvant_JJ
chemotherapy_NN
with_IN
CMF_NN
and_CC
in_IN
those_DT
receiving_VBG
continued_JJ
adjuvant_JJ
tamoxifen_NN
treatment_NN
-LRB-_-LRB-
P_NN
&gt;_JJR
0.1_CD
-RRB-_-RRB-
,_,
but_CC
in_IN
all_DT
patients_NNS
still_RB
significantly_RB
decreased_VBD
as_IN
compared_VBN
with_IN
healthy_JJ
controls_NNS
-LRB-_-LRB-
P_NN
&lt;_JJR
0.001_CD
-RRB-_-RRB-
._.

When_WRB
data_NNS
obtained_VBN
preoperatively_RB
and_CC
after_IN
12_CD
months_NNS
were_VBD
compared_VBN
,_,
it_PRP
was_VBD
found_VBN
that_IN
out_RB
of_IN
23_CD
patients_NNS
whose_WP$
PBMCs_NNS
had_VBD
experienced_VBN
a_DT
drop_NN
in_IN
their_PRP$
PHA-induced_JJ
proliferation_NN
,_,
14_CD
-LRB-_-LRB-
61_CD
%_NN
-RRB-_-RRB-
had_VBD
developed_VBN
metastatic_JJ
disease_NN
within_IN
the_DT
subsequent_JJ
24_CD
months_NNS
-LRB-_-LRB-
i.e._FW
36_CD
months_NNS
after_IN
surgery_NN
-RRB-_-RRB-
._.

In_IN
contrast_NN
,_,
out_RB
of_IN
59_CD
patients_NNS
whose_WP$
PBMCs_NNS
showed_VBD
an_DT
increase_NN
in_IN
their_PRP$
PHA-induced_JJ
proliferation_NN
within_IN
the_DT
first_JJ
12_CD
months_NNS
after_IN
surgery_NN
,_,
only_RB
one_CD
-LRB-_-LRB-
2_CD
%_NN
-RRB-_-RRB-
presented_VBD
with_IN
disease_NN
progression_NN
._.

We_PRP
thus_RB
conclude_VBP
that_IN
PHA-induced_JJ
proliferation_NN
of_IN
PBMCs_NNS
derived_VBN
from_IN
patients_NNS
with_IN
breast_NN
cancer_NN
depends_VBZ
upon_IN
the_DT
tumor_NN
load_NN
and_CC
is_VBZ
a_DT
good_JJ
clinical_JJ
predictor_NN
for_IN
the_DT
further_JJ
course_NN
of_IN
the_DT
disease_NN
._.

